{"product_id":"chek-vrio-analysis","title":"Check-Cap Ltd. (CHEK): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Check-Cap Ltd. (CHEK)'s enduring success by diving into this critical VRIO Analysis. We've rigorously tested the firm's core assets against the pillars of Value, Rarity, Inimitability, and Organization to pinpoint exactly where sustainable competitive advantage is forged. This distilled summary offers a strategic glimpse - read on below to explore the full, in-depth findings that define Check-Cap Ltd. (CHEK)'s market position.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCheck-Cap Ltd. (CHEK) - VRIO Analysis: 1. Capsule-Based Screening Technology (Core Product IP)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Check-Cap Ltd.’s C-Scan® technology right as the company pivots hard into embodied AI via the MBody AI merger. The core question for this asset is whether its medical innovation can survive the transition and secure a market foothold.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Disruption Potential\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe C-Scan® system offers a preparation-free, minimally invasive alternative to colonoscopy for colorectal cancer screening, using an ingestible X-ray emitting capsule and external detectors. This addresses major patient compliance hurdles. For a company with a market capitalization around \u003cstrong\u003e$9.7 million\u003c\/strong\u003e as of late 2025, this technology represents its primary, high-value asset. It’s definitely a potential game-changer in diagnostics. \u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Unique Form Factor\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific combination of an ingestible, low-dose X-ray capsule propelled by natural motility is likely rare among active screening devices today. Stool-based tests don't offer visualization, and traditional colonoscopy requires sedation and prep. This capsule’s mechanism is, for now, quite unique in the market landscape. \u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Engineering and Validation Barriers\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReplicating this technology is tough. It requires deep expertise in miniaturized medical device engineering, low-dose X-ray emission control within the body, and proprietary image reconstruction algorithms. Plus, any competitor faces the massive hurdle of securing the necessary clinical validation and FDA\/CE mark approvals, which takes years and millions in capital. \u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Post-Merger Integration\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis is where the near-term risk lies. Value realization is highly uncertain; it hinges entirely on how MBody AI, now set to be the combined entity after shareholders approved the merger with \u003cstrong\u003e98.01%\u003c\/strong\u003e of votes cast, chooses to integrate or prioritize this medical asset versus its core embodied AI platform. If the tech gets sidelined, its value erodes fast. \u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage Assessment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is \u003cstrong\u003ePotentially Sustained\u003c\/strong\u003e, but only if the MBody AI leadership commits resources to push the C-Scan® through pivotal trials and commercialization, backed by strong, existing patents. If they don't, it defaults to a temporary advantage or even a stranded asset. \u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO dimensions:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eImplication\u003c\/td\u003e\n    \u003ctd\u003eScore (1-4)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eHigh potential to improve patient compliance for CRC screening.\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity to Temporary Advantage\u003c\/td\u003e\n    \u003ctd\u003e3\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eUnique ingestible, preparation-free, low-dose X-ray imaging system.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003e3\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eHigh due to complex engineering and regulatory barriers.\u003c\/td\u003e\n    \u003ctd\u003eUnused Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003e3\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eUncertain; dependent on MBody AI's strategic commitment post-merger.\u003c\/td\u003e\n    \u003ctd\u003ePotential for Sustained Advantage\u003c\/td\u003e\n    \u003ctd\u003e2\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the current balance sheet stress; Check-Cap's working capital was negative at \u003cstrong\u003e$1,546,000\u003c\/strong\u003e before the merger, meaning the C-Scan R\u0026amp;D needs immediate, deep funding from the new entity.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n  \u003cli\u003eResource Category: Proprietary Medical IP (C-Scan®).\u003c\/li\u003e\n  \u003cli\u003eKey Risk: Strategic neglect post-merger.\u003c\/li\u003e\n  \u003cli\u003eActionable Insight: Demand clear milestones for C-Scan® in the new MBody AI operating plan.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft the pro-forma 13-week cash flow view incorporating the MBody AI merger structure by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCheck-Cap Ltd. (CHEK) - VRIO Analysis: 2. Nasdaq Listing Compliance (Access to Public Capital)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides access to U.S. equity markets for potential future financing, crucial given the recent equity concerns. The stock was trading at \u003cstrong\u003e$28.29\u003c\/strong\u003e as of mid-October 2025, significantly up from its 52-week low of \u003cstrong\u003e$19.99\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Common for US-listed firms, but regaining compliance after a deficiency is a temporary, hard-won status. The company received a deficiency letter in \u003cstrong\u003eApril\u003c\/strong\u003e 2025 regarding the minimum bid price rule.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; compliance rules are public, but meeting the bid price and equity thresholds is a specific operational hurdle.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good, as they confirmed regaining minimum bid price compliance on \u003cstrong\u003eSeptember 29, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the stockholders' equity rule compliance (requiring \u0026gt;\u003cstrong\u003e$2.5 million\u003c\/strong\u003e) was still pending confirmation as of early \u003cstrong\u003eOctober 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe status of Nasdaq compliance as of the latest reported updates is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eNasdaq Listing Rule\u003c\/td\u003e\n\u003ctd\u003eRequirement Threshold\u003c\/td\u003e\n\u003ctd\u003eCompliance Status (as of Oct 2025)\u003c\/td\u003e\n\u003ctd\u003eKey Date\/Basis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRule 5550(a)(2) (Minimum Bid Price)\u003c\/td\u003e\n\u003ctd\u003eClosing bid price $\\ge$ \u003cstrong\u003e$1.00\u003c\/strong\u003e for 10 consecutive trading days\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRegained Compliance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eConfirmed \u003cstrong\u003eSeptember 29, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRule 5550(b)(1) (Stockholders' Equity)\u003c\/td\u003e\n\u003ctd\u003eStockholders' Equity $\\ge$ \u003cstrong\u003e$2,500,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePending Confirmation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUnaudited data for six months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e showed equity significantly exceeds \u003cstrong\u003e$2.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRule 5250(c)(1) (Timely Filings)\u003c\/td\u003e\n\u003ctd\u003eTimely filing of periodic financial reports\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eCompliant\u003c\/strong\u003e (Matter Closed)\u003c\/td\u003e\n\u003ctd\u003eFiling of Form 20-F for year ended \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e on \u003cstrong\u003eAugust 27, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther details regarding the equity compliance deficiency and the bid price compliance are:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe stockholders' equity deficiency notice was received on \u003cstrong\u003eSeptember 4, 2025\u003c\/strong\u003e, with a deadline of \u003cstrong\u003eOctober 20, 2025\u003c\/strong\u003e, to submit a plan to regain compliance under Rule 5550(b)(1).\u003c\/li\u003e\n\u003cli\u003eThe company reported a share price increase of more than \u003cstrong\u003e300%\u003c\/strong\u003e following the merger announcement with MBody AI.\u003c\/li\u003e\n\u003cli\u003eThe minimum bid price compliance required the ordinary shares to close at \u003cstrong\u003e$1.00\u003c\/strong\u003e or greater for \u003cstrong\u003eten consecutive trading days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCheck-Cap Ltd. (CHEK) - VRIO Analysis: 3. Acquired Ghost Kitchen Franchise Rights (Diversification Asset)\n\u003c\/h2\u003e\n\u003cp\u003eThe acquisition of exclusive Ghost Kitchen franchise rights in New Jersey represents a non-core diversification strategy for Check-Cap Ltd. (CHEK), executed via an Asset Purchase Agreement with Parea LLC on September 5, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The asset provides a potential non-medical revenue stream derived from the expansion of Ghost Kitchen operations within New Jersey. The company is entitled to receive 50% of all initial franchise fees and 50% of all ongoing royalties actually paid by New Jersey franchisees.\u003c\/p\u003e\n\n\u003cp\u003eThe quantifiable terms of this diversification asset are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eValue\/Percentage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Acquired\u003c\/td\u003e\n\u003ctd\u003eExclusive Franchise Rights Territory\u003c\/td\u003e\n\u003ctd\u003eNew Jersey\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Stream Share\u003c\/td\u003e\n\u003ctd\u003eInitial Franchise Fees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Stream Share\u003c\/td\u003e\n\u003ctd\u003eOngoing Royalties\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Date\u003c\/td\u003e\n\u003ctd\u003eAsset Purchase Agreement Execution\u003c\/td\u003e\n\u003ctd\u003eSeptember 5, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsideration Paid (Shares)\u003c\/td\u003e\n\u003ctd\u003eOrdinary Shares Issued to Parea LLC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,169,596\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The holding of exclusive franchise rights for a Ghost Kitchen model is rare for a company primarily focused on medical diagnostics, marking this asset as a unique, non-core diversification.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The rights are considered low in imitability in the short term because they were secured through a specific, executed Asset Purchase Agreement with Parea LLC, establishing exclusivity within the defined territory.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company demonstrated organizational commitment to this non-core growth by issuing 1,169,596 ordinary shares as consideration for the asset acquisition. Contextually, the company's overall market capitalization was reported as $3.79M, and it was simultaneously addressing a Nasdaq compliance deficiency related to stockholders' equity, which required a minimum of $2,500,000.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e The advantage derived from this asset is considered \u003cstrong\u003eTemporary\u003c\/strong\u003e. Its value is directly contingent upon the success and expansion rate of the Ghost Kitchen franchise market within New Jersey and is not intrinsically linked to Check-Cap's long-term medical device mission.\u003c\/p\u003e\n\n\u003cp\u003eFurther operational context includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAverage Trading Volume reported as 176,038.\u003c\/li\u003e\n\u003cli\u003eThe company must submit a plan to regain Nasdaq compliance by October 20, 2025, following the receipt of a deficiency letter on September 3, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCheck-Cap Ltd. (CHEK) - VRIO Analysis: 4. Post-Merger Strategic Direction (Agreement with MBody AI)\n\u003c\/h2\u003e\n\u003cp\u003e\nThe definitive merger agreement between Check-Cap Ltd. and MBody AI, dated September 12, 2025, signals a substantial strategic pivot for the entity, now slated to be renamed 'MBody AI Ltd.'.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Signals a pivot or significant enhancement to the business model, potentially addressing capital needs and technology gaps.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe stock experienced a surge of 360% in premarket trading following the announcement, reaching a peak of $3.67 pre-market.\u003c\/li\u003e\n\u003cli\u003eThe merger is positioned as a solution to Check-Cap's compliance issues with Nasdaq's minimum stockholders' equity requirement.\u003c\/li\u003e\n\u003cli\u003eThe combined entity plans to secure financing through a private placement on mutually acceptable terms.\u003c\/li\u003e\n\u003cli\u003eCheck-Cap's legacy assets, including patents and proprietary medical equipment, are retained by the merged company.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific merger terms and the combination of a diagnostics firm with an AI entity are unique.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUnder the agreement terms, current MBody AI equityholders will own 90% of the combined company on a fully diluted basis.\u003c\/li\u003e\n\u003cli\u003eCurrent Check-Cap shareholders will retain 10% of the combined entity.\u003c\/li\u003e\n\u003cli\u003eThe merger is expected to create potential synergies with Check-Cap's Ghost Kitchen franchise rights in New Jersey.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; merger agreements are unique contracts, though the strategy of merging is common.\n\u003c\/p\u003e\n\u003cp\u003e\nThe specific contractual terms, including the 90% to 10% post-merger equity split and the integration of Check-Cap's legacy assets with MBody AI's proprietary AI stack, constitute a unique agreement structure.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High, as the board is actively evaluating financing and has executed the merger agreement, showing decisive action.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShareholders approved the merger with 98.01% of votes cast in favor at the Annual General Meeting held on November 14, 2025.\u003c\/li\u003e\n\u003cli\u003eBoard re-elections were confirmed, with David Lontini re-elected as active chairman with 98.96% of votes cast in favor.\u003c\/li\u003e\n\u003cli\u003eThe company's Average Trading Volume was reported as 2,969,064.\u003c\/li\u003e\n\u003cli\u003ePrior to the vote, the Market Cap was reported at $13.87M, with Insider Ownership at 20.82% and Institutional Ownership at 1.73%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Potentially Sustained; the combined entity's success hinges on integrating the AI capabilities with the diagnostic platform.\n\u003c\/p\u003e\n\u003cp\u003e\nThe potential competitive advantage is derived from MBody AI's claimed performance metrics in enterprise deployments of its Orchestrator platform.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric Category\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eValue\/Percentage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Merger Financial Health (CHEK)\u003c\/td\u003e\n\u003ctd\u003eNegative EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-1.06\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Merger Financial Health (CHEK)\u003c\/td\u003e\n\u003ctd\u003eNegative Return on Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-39.72%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Merger Balance Sheet (CHEK)\u003c\/td\u003e\n\u003ctd\u003eWorking Capital\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$1,546,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerger Structure\u003c\/td\u003e\n\u003ctd\u003eMBody AI Ownership Stake\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerger Structure\u003c\/td\u003e\n\u003ctd\u003eCheck-Cap Ownership Stake\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMBody AI Performance Claim\u003c\/td\u003e\n\u003ctd\u003eLabor Reduction\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e40%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMBody AI Performance Claim\u003c\/td\u003e\n\u003ctd\u003eUptime Improvement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholder Approval Rate\u003c\/td\u003e\n\u003ctd\u003eVotes in Favor of Merger\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e98.01%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eCheck-Cap Ltd. (CHEK) - VRIO Analysis: 5. Intellectual Property Portfolio (Patents and Trade Secrets)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates a barrier to entry for competitors attempting to replicate the capsule technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High, as proprietary medical device IP is difficult and expensive to develop from scratch.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very difficult; requires years of R\u0026amp;D and navigating complex patent law.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Assumed High; a clinical-stage company must have its IP organized to defend it, though specific patent counts aren't public here.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this is the classic source of advantage in the med-tech space.\u003c\/p\u003e\n\n\u003cp\u003eThe Intellectual Property portfolio is anchored by the C-Scan® technology and associated trademarks.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTrademarks owned include \u003cstrong\u003e'CHECK-CAP'\u003c\/strong\u003e and \u003cstrong\u003e'C-Scan'\u003c\/strong\u003e design logos.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe quantitative scope of the patent portfolio includes:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patents (Worldwide)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 2, 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample Granted Patent (US) - Tracking Tech\u003c\/td\u003e\n\u003ctd\u003ePatent No. \u003cstrong\u003e11147468\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIssued October 19, 2021; Valid through May 2034\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample Granted Patent (US) - Nano Particle Detection\u003c\/td\u003e\n\u003ctd\u003ePatent No. \u003cstrong\u003e10098599\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIssued October 16, 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample Granted Patent (US) - Polyp Detection via Dynamics\u003c\/td\u003e\n\u003ctd\u003ePatent No. \u003cstrong\u003e12138033\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIssued November 12, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company has historically recorded Research and Development Expenses, which include costs related to patent legal fees, as part of its operating structure.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the three-month periods ended November 30, 2024, and 2023, included line items for \u003cstrong\u003ePatent legal fees\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCheck-Cap Ltd. (CHEK) - VRIO Analysis: 6. Unaudited Stockholders' Equity Position (H1 2025)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe unaudited stockholders' equity position for H1 2025 provides a baseline measure of the balance sheet health, which previously triggered a compliance notice from Nasdaq under Listing Rule 5550(b)(1). The reported unaudited figure for the six months ended June 30, 2025, \u003cstrong\u003esignificantly exceeds $2.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eReference Period\/Rule\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNasdaq Minimum Stockholders' Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,500,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNasdaq Listing Rule 5550(b)(1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnaudited Stockholders' Equity\u003c\/td\u003e\n\u003ctd\u003eSignificantly exceeds \u003cstrong\u003e$2,500,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eH1 2025 (Six months ended June 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevious Non-Compliance Threshold Breach\u003c\/td\u003e\n\u003ctd\u003eBelow \u003cstrong\u003e$2,500,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNotice received prior to September 5, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$9.42 million\u003c\/strong\u003e or \u003cstrong\u003e$10.88 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNovember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe stockholders' equity level itself is not inherently rare, but the specific magnitude relative to the Nasdaq minimum threshold is critical for continued listing status.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNasdaq Listing Rule 5550(b)(1) Requirement: \u003cstrong\u003e$2,500,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eH1 2025 Unaudited Position: Stated to be above the \u003cstrong\u003e$2,500,000\u003c\/strong\u003e minimum.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable; the reported stockholders' equity figure for H1 2025 is a historical financial fact derived from the company's unaudited statements.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOrganization is assessed as moderate based on the internal reporting and subsequent external notification process.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company reported that its unaudited H1 2025 statements indicated equity exceeds \u003cstrong\u003e$2.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFormal confirmation from Nasdaq regarding compliance with the equity rule was pending as of October 16, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company previously had 45 calendar days, until October 20, 2025, to submit a plan to regain compliance following a deficiency notice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone; maintaining stockholders' equity above the \u003cstrong\u003e$2,500,000\u003c\/strong\u003e threshold is a necessary condition for Nasdaq listing compliance, not a source of sustainable competitive advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCheck-Cap Ltd. (CHEK) - VRIO Analysis: 7. Institutional Investor Interest (Post-Merger Buzz)\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: Indicates external validation of the combined company's future strategy, potentially easing future capital raises.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: Rare for a company that recently faced compliance issues; this suggests strong belief in the MBody AI component.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePre-Merger Context (Approx. Sep 12, 2025)\u003c\/th\u003e\n\u003cth\u003ePost-Merger Buzz (Post-Announcement)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price Movement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.7459\u003c\/strong\u003e (Sep 12, 2025)\u003c\/td\u003e\n\u003ctd\u003eIncrease of more than \u003cstrong\u003e300%\u003c\/strong\u003e \/ Jumped \u003cstrong\u003e390%\u003c\/strong\u003e to \u003cstrong\u003e$3.67\u003c\/strong\u003e (pre-market)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrading Volume\u003c\/td\u003e\n\u003ctd\u003eAverage Trading Volume: \u003cstrong\u003e182,134\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReached \u003cstrong\u003ehundreds of millions of dollars\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.01M\u003c\/strong\u003e \/ \u003cstrong\u003e$4.39 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$11.65 million\u003c\/strong\u003e (Nov 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional Ownership\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.82%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStrong institutional interest expressed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Merger Financial Health\u003c\/td\u003e\n\u003ctd\u003eForecasted 2025 Revenue: \u003cstrong\u003e$0 million\u003c\/strong\u003e; Forecasted 2025 EBIT: \u003cstrong\u003e-$17 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eStockholders' equity exceeded \u003cstrong\u003e$2.5 million\u003c\/strong\u003e as of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nImitability: Low; this interest is a reaction to specific, recent events (merger announcement).\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: High; the company is actively engaging with interested investors and banks to explore financing options.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Board is evaluating potential financing opportunities to strengthen the capital position.\u003c\/li\u003e\n\u003cli\u003eInbound investment inquiries for MBody AI reached \u003cstrong\u003ehundreds of millions of dollars\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe companies stated they will use 'commercially reasonable efforts' to secure a private placement financing on mutually acceptable terms.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nCompetitive Advantage: Temporary; this positive sentiment can evaporate quickly if financing or integration falters.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCheck-Cap Ltd. (CHEK) - VRIO Analysis: 8. Management's Experience in Corporate Turnaround\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to navigate complex regulatory hurdles (Nasdaq compliance) and execute a major strategic shift (merger\/acquisition).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRegained compliance with Nasdaq minimum bid price requirement on \u003cstrong\u003eSeptember 29\u003c\/strong\u003e after closing at \u003cstrong\u003e$1.00\u003c\/strong\u003e or greater for ten consecutive trading days.\u003c\/li\u003e\n\u003cli\u003eStockholders' equity, based on unaudited financial statements for the six months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, significantly exceeds the \u003cstrong\u003e$2.5 million\u003c\/strong\u003e minimum required under Nasdaq Listing Rule 5550(b)(1).\u003c\/li\u003e\n\u003cli\u003eExecuted Agreement and Plan of Merger with MBody AI on \u003cstrong\u003eSeptember 12, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many small-cap executives have faced delisting threats, but executing a successful pivot is less common.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStock soared \u003cstrong\u003e360%\u003c\/strong\u003e in premarket trading following the definitive merger agreement announcement.\u003c\/li\u003e\n\u003cli\u003eStock trended up by \u003cstrong\u003e323.65%\u003c\/strong\u003e on \u003cstrong\u003eMonday, September 15, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; relies on the specific network and prior experience of the leadership team.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eChairman of the Board of Directors and Interim CEO David Lontini was re-elected with \u003cstrong\u003e98.96%\u003c\/strong\u003e of votes cast in favor.\u003c\/li\u003e\n\u003cli\u003eBoard member Michael Hutton was re-elected with \u003cstrong\u003e98.01%\u003c\/strong\u003e of votes cast in favor.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; demonstrated by regaining bid price compliance and executing the merger agreement in late 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShareholders approved the merger with MBody AI with \u003cstrong\u003e98.01%\u003c\/strong\u003e of votes cast in favor.\u003c\/li\u003e\n\u003cli\u003eThe company filed its annual report on Form 20-F for the year ended \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e, on \u003cstrong\u003eAugust 27\u003c\/strong\u003e, closing the matter regarding timely filing compliance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this advantage is only sustained if the current leadership remains in place and delivers results.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\/Event\u003c\/th\u003e\n\u003cth\u003eDate\/Value\u003c\/th\u003e\n\u003cth\u003eReference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerger Agreement Execution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 12, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNasdaq Bid Price Compliance Regained\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 29\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price at Update Post-Compliance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.29\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholder Approval for Merger\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e98.01%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMBody AI Post-Merger Ownership\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCheck-Cap Shareholder Post-Merger Ownership\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockholders' Equity (as of 6\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003eExceeds \u003cstrong\u003e$2.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProposed Reverse Split Range\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1-for-14 to 1-for-100\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eCheck-Cap Ltd. (CHEK) - VRIO Analysis: 9. Market Volatility Response (Stock Performance)\n\u003c\/h2\u003e\n\u003cp\u003eThe market response to the MBody AI merger announcement demonstrated significant, albeit temporary, valuation impact on Check-Cap Ltd. stock.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe stock experienced an increase of up to \u003cstrong\u003e383.98%\u003c\/strong\u003e on the day of the MBody AI merger announcement, reaching a high of \u003cstrong\u003e$3.67\u003c\/strong\u003e in pre-market trading on one report, and a \u003cstrong\u003e223.62%\u003c\/strong\u003e increase to \u003cstrong\u003e$2.22\u003c\/strong\u003e on a related date.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe magnitude of the single-day percentage move, such as the \u003cstrong\u003e383.98%\u003c\/strong\u003e surge, is a rare occurrence for a company of CHEK's prior market capitalization and trading profile.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe specific market reaction is tied directly to the definitive merger agreement with MBody AI and the resulting shift in business focus to embodied AI, making the exact price movement non-imitable by competitors.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe organization successfully leveraged the announcement to generate substantial trading activity, with approximately \u003cstrong\u003e67 million shares\u003c\/strong\u003e changing hands on the announcement day, compared to a three-month daily average of about \u003cstrong\u003e1 million units\u003c\/strong\u003e. The resulting trading volumes were reported in the \u003cstrong\u003ehundreds of millions of dollars\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe volatility indicates high market attention but does not constitute a sustainable competitive advantage; the advantage, if any, lies in the potential synergies of the combined entity.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eMarket Data Summary\u003c\/h\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Reported Stock Increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e383.98%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOn the day of the MBody AI merger announcement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Trading Volume (Day of News)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67 million shares\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to a 3-month average of \u003cstrong\u003e1 million units\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Trading Volume Magnitude\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eHundreds of millions of dollars\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFollowing the merger announcement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Market High Price (Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.67\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported on Monday following the announcement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price on Related Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.22\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported after a \u003cstrong\u003e223.62%\u003c\/strong\u003e increase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Merger Shareholder Ownership (Projected)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCheck-Cap shareholders retaining stake post-merger.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eStock Performance Context\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe stock was down \u003cstrong\u003e24.66%\u003c\/strong\u003e year-to-date and down \u003cstrong\u003e59.02%\u003c\/strong\u003e over the past 12 months prior to the merger news.\u003c\/li\u003e\n\u003cli\u003eThe merger is subject to approval by Check-Cap shareholders at the Annual General Meeting scheduled for October 17, 2025.\u003c\/li\u003e\n\u003cli\u003eThe combined company is expected to be renamed 'MBody AI Ltd.'\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eFinance\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eReal-life statistical and financial numbers for the pro-forma cash flow statement incorporating the Parea LLC share issuance by Friday are not available in the current data set.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516135596181,"sku":"chek-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/chek-vrio-analysis.png?v=1740159266","url":"https:\/\/dcf-model.com\/fr\/products\/chek-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}